EMEA-001720-PIP01-14-M02 - paediatric investigation plan

Patiromer calcium

Key facts

• Invented name:
  • Veltassa
  • Veltassa
• Active Substance:
  Patiromer calcium
• Therapeutic area:
  Other
• Decision number:
  P/0367/2021
• PIP number:
  EMEA-001720-PIP01-14-M02
• Pharmaceutical form(s):
  Powder for oral suspension
• Condition(s) / indication(s):
  Treatment of hyperkalaemia
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Vifor Fresenius Medical Care Renal Pharma France

  Tel. [phone]; E-mail: [e-mail]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  08/09/2021

Decision

P/0367/2021 : EMA decision of 8 September 2021 on the acceptance of a modification of an agreed paediatric investigation plan for patiromer calcium (Veltassa), (EMEA-001720-PIP01-14-M02)

AdoptedReference Number: EMA/418749/2021